ASN
VERV

Advisory Services Network’s Verve Therapeutics VERV Stock Holding History

Advisory Services Network’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14
Closed -$202 – 3575
2023
Q1 		$202 Buy
+14
New +$274 ﹤0.01% 3841

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Advisory Services Network's VERV Position: Q2 2023 in Review

Advisory Services Network sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 14 shares — an estimated $202 sold.

Advisory Services Network first reported a position in VERV in Q1 2023 and held it in 1 quarter. The position peaked at $202 in Q1 2023. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • Advisory Services Network reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Advisory Services Network sold 14 Verve Therapeutics shares in Q2 2023, an estimated $202.
  • Advisory Services Network first reported a position in Verve Therapeutics in Q1 2023 and held it in 1 quarter.
  • Advisory Services Network's Verve Therapeutics position peaked at $202 in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.